Daquiran

pramipexole

The marketing authorisation for Daquiran has been withdrawn at the request of the marketing authorisation holder. 

This EPAR was last updated on 23/05/2006 .

More detail is available in the summary of product characteristics

Product details

Publication details

Product information

02/02/2006  Daquiran -EMEA/H/C/000135

Contents

• Annex I - Summary of product characteristics
• Annex IIA - Manufacturing-authorisation holder responsible for batch release
• Annex IIB - Conditions of the marketing authorisation
• Annex IIIA - Labelling
• Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Anti-parkinson drugs

Therapeutic indication

DAQUIRAN tablets are indicated for treatment of the signs and symptoms of advanced idiopathic Parkinson's disease in combination with levodopa, i.e. over the course of the disease, when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end of dose or "on off" fluctuations).

Changes since initial authorisation of medicine

Initial marketing-authorisation documents